Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CPIX
Upturn stock ratingUpturn stock rating

Cumberland Pharmaceuticals Inc (CPIX)

Upturn stock ratingUpturn stock rating
$3.35
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CPIX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $8.5

1 Year Target Price $8.5

Analysts Price Target For last 52 week
$8.5Target price
Low$1.04
Current$3.35
high$7.25

Analysis of Past Performance

Type Stock
Historic Profit 20.54%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 38.90M USD
Price to earnings Ratio -
1Y Target Price 8.5
Price to earnings Ratio -
1Y Target Price 8.5
Volume (30-day avg) 1
Beta -0.29
52 Weeks Range 1.04 - 7.25
Updated Date 06/30/2025
52 Weeks Range 1.04 - 7.25
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.24

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -7.98%
Operating Margin (TTM) 11.03%

Management Effectiveness

Return on Assets (TTM) -2.7%
Return on Equity (TTM) -11.86%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 34231424
Price to Sales(TTM) 0.95
Enterprise Value 34231424
Price to Sales(TTM) 0.95
Enterprise Value to Revenue 0.83
Enterprise Value to EBITDA 10.52
Shares Outstanding 14961100
Shares Floating 7940923
Shares Outstanding 14961100
Shares Floating 7940923
Percent Insiders 41.54
Percent Institutions 28.76

Analyst Ratings

Rating 1
Target Price 8.5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cumberland Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Cumberland Pharmaceuticals Inc. was founded in 1999 and is headquartered in Nashville, Tennessee. The company focuses on the acquisition, development, and commercialization of branded prescription products. Initially concentrating on hospital products, Cumberland has expanded into broader therapeutic areas through strategic acquisitions and internal development.

business area logo Core Business Areas

  • Hospital Products: This segment focuses on providing branded prescription products for the acute care hospital setting. Key products include Caldolor (ibuprofen injection) and Ofirmev (acetaminophen injection).
  • Gastrointestinal Products: This segment includes prescription products that are designed for the relief of various symptoms associated with gastrointestinal issues.
  • Dermatology: This segment includes prescription products that are designed for dermatological needs, particularly treatment of skin-related diseases

leadership logo Leadership and Structure

Cumberland Pharmaceuticals Inc. is led by a team of executives with experience in the pharmaceutical industry. The structure is organized around functional areas, including research and development, sales and marketing, and finance and operations. The CEO is John Hammann.

Top Products and Market Share

overview logo Key Offerings

  • Ofirmev (acetaminophen injection): Ofirmev is an intravenous formulation of acetaminophen used for pain management and fever reduction in hospitals. Competitors include generic acetaminophen injections, IV ibuprofen and opioid analgesics. Market share data is not publicly available, but Ofirmev is a leading brand in its niche.
  • Caldolor (ibuprofen injection): Caldolor is an intravenous formulation of ibuprofen used for pain management and fever reduction in hospitals. Competitors include generic ibuprofen injections, IV acetaminophen, and opioid analgesics. Market share data is not publicly available, but Caldolor is a significant player in the market.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Increasing generic competition and pricing pressures are significant challenges. Technological advancements and personalized medicine are driving innovation.

Positioning

Cumberland Pharmaceuticals Inc. occupies a niche position, focusing on hospital-based and specialty pharmaceuticals. Its competitive advantages include established brands and a focused portfolio of products.

Total Addressable Market (TAM)

The TAM for acute pain and fever management is estimated to be several billion dollars annually in the US. Cumberland is positioned to capture a portion of this TAM through its hospital-based products.

Upturn SWOT Analysis

Strengths

  • Established brands in niche markets
  • Focused product portfolio
  • Experienced management team
  • Strong relationships with hospitals

Weaknesses

  • Small market capitalization
  • Reliance on a limited number of products
  • Limited R&D pipeline
  • Vulnerability to generic competition

Opportunities

  • Strategic acquisitions
  • New product development
  • Geographic expansion
  • Partnerships and collaborations

Threats

  • Generic competition
  • Pricing pressures
  • Regulatory changes
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • Pacira BioSciences (PCRX)
  • Assertio Holdings (ASRT)
  • Mallinckrodt (MNK)

Competitive Landscape

Cumberland faces competition from both generic and branded pharmaceutical companies. Its advantages include established brands in niche markets, while its disadvantages include limited scale and R&D resources.

Growth Trajectory and Initiatives

Historical Growth: Cumberland's growth has been driven by product sales and strategic acquisitions. Growth rates have varied depending on product performance and market conditions.

Future Projections: Future growth is dependent on new product launches, market penetration, and cost management. Analyst estimates vary widely depending on the company's performance and market conditions.

Recent Initiatives: Recent initiatives include new product launches and collaborations to expand their portfolio.

Summary

Cumberland Pharmaceuticals is a niche player with established hospital products and growth potential. Its small size and reliance on a limited number of products pose challenges. The company must continue to diversify its product portfolio through acquisitions and internal development. Success will depend on execution, cost control, and navigating the evolving pharmaceutical landscape. The company has to beware of competition from generic brands.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change. Accuracy of financial data is dependent on reliable sources. Market share data can be estimates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cumberland Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Nashville, TN, United States
IPO Launch date 2009-08-11
Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 91
Full time employees 91

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.